Eisai Co Ltd (ESALY.PK)
* Positive topline results of large phase 3 trial show Eisai's lenvatinib meets primary endpoint in unresectable hepatocellular carcinoma
ZURICH, Jan 16 The Swiss blue-chip SMI was seen opening 0.2 percent easier at 8,436 points on Monday, according to premarket indications by bank Julius Baer .
Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.
* Eisai inc - first phase 3 study for e2609 in clinical trial program will enroll 1,330 patients with biomarkers confirmed for early alzheimer's disease
LONDON Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.
LONDON, Nov 3 Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.
|Johnson & Johnson (JNJ.N)||$126.58||+0.32|
|GlaxoSmithKline plc (GSK.L)||1,675.00||+4.50|
|Novartis AG (NOVN.S)||CHF74.15||+0.75|
|Merck & Co., Inc. (MRK.N)||$63.49||-0.01|
|AstraZeneca plc (AZN.L)||4,959.50||+107.00|
|Pfizer Inc. (PFE.N)||$34.44||-0.03|
|Bristol-Myers Squibb Co (BMY.N)||$56.00||-0.36|
|Bristol-Myers Squibb Co (BMYMP.PK)||$1,050.00||--|
|Sanofi SA (SASY.PA)||€83.30||+0.53|
|Roche Holding Ltd. (ROG.S)||CHF252.60||+2.40|